US91381U2006 - Common Stock
UNITY BIOTECHNOLOGY INC
NASDAQ:UBX (3/28/2024, 8:00:02 PM)
After market: 1.58 -0.06 (-3.66%)1.64
+0.01 (+0.61%)
Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 32 full-time employees. The company went IPO on 2018-05-03. The firm is focused on creating medicines to selectively eliminate or modulate senescent cells. The firm is also focused on advancing senolytic programs primarily in ophthalmologic disorders. The company is also focused on advancing other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/vascular endothelial growth factor (VEGF) bispecific to treat vascular eye disease. The firm's UBX1325 and UBX1967 are designed to inhibit the function of proteins that senescent cells rely on for survival. UBX1325 is an advanced drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration, (AMD), and diabetic retinopathy (DR). Its UBX2050 is an investigational, fully human anti-Tie2 agonist monoclonal antibody.
UNITY BIOTECHNOLOGY INC
285 East Grand Avenue
South San Francisco CALIFORNIA
P: 16504161192
Employees: 32
Website: https://unitybiotechnology.com/
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing...
In this article, we are going to discuss the 10 Supplements for Longevity and Antiaging: Expert Recommendations. You can skip our detailed analysis and go directly to 5 Supplements for Longevity and Antiaging: Expert Recommendations. The anti-aging and longevity market is undergoing a fascinating transformation, driven by personalized approaches, cutting-edge science, and a growing emphasis on evidence-based […]
Topline 16-week data expected in the fourth quarter of 2024
Unity Biotechnology has filed a prospectus for the resale of up to 2,271,580 shares of common stock. This is not an offer to sell.
Wedbush upgrades Unity Biotechnology (UBX) to outperform, citing extension of the company's cash runway. Read more here.
Here you can normally see the latest stock twits on UBX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: